Variables | With CRa n = 57 | Without CRa n = 20 | OR (95% CI) | p |
---|---|---|---|---|
Demographic parameters | ||||
Age, year | 59.4 (18.9) | 63.09 (16.3) | 0.464 | |
Female gender | 16 (28.1%) | 9 (45.0%) | 0.48 (0.17–1.37) | 0.164 |
Comorbidities | ||||
Hepatic dysfunction | 2 (3.5%) | 0 (0.0%) | 0.73 (0.64–0.84) | 1.000 |
Renal insufficiency | 6 (10.5%) | 1 (5.0%) | 2.24 (0.25–19.80) | 0.669 |
Chronic pulmonary disease | 14 (24.6%) | 7 (35.0%) | 0.60 (0.20–1.82) | 0.367 |
Heart disease | 11 (19.3%) | 2 (10.0%) | 2.15 (0.43–10.68) | 0.495 |
Diabetes mellitus | 3 (5.3%) | 1 (5.0%) | 1.06 (0.10–10.77) | 1.000 |
Immune compromise | 3 (5.3%) | 2 (10.0%) | 0.50 (0.08–3.23) | 0.600 |
Malignancy | 5 (8.8%) | 2 (10.0%) | 0.86 (0.15–4.86) | 1.000 |
Hypoproteinemia | 1 (1.8%) | 1 (5.0%) | 0.34 (0.20–5.69) | 0.455 |
Surgery | 11 (19.3%) | 5 (25.0%) | 0.72 (0.22–2.34) | 0.749 |
Clinical conditions | ||||
CURB65 score, mean ± SD | 2.4 (0.6) | 1.9 (1.1) | 0.006 | |
Mechanical ventilation | 31 (64.6%) | 17 (85.0%) | 0.21 (0.06–0.80) | 0.015 |
Albumin | 31.7 (5.7) | 32.2 (4.0) | 0.512 | |
Microbiology | ||||
Bacteremia | 2 (3.5%) | 5 (25.0%) | 0.11 (0.02–0.62) | 0.011 |
Tigecycline resistance | 33 (57.9%) | 9 (45.0%) | 1.68 (0.60–4.69) | 0.319 |
Airway eradication of MDRAB | 21 (51.2%) | 3 (18.8%) | 4.55 (1.13–18.39) | 0.026 |
Tigecycline treatment | ||||
Duration, days | 8.4 (3.7) | 12.9 (6.4) | 0.001 | |
Combination therapy | ||||
With sulbactam | 49 (86.0%) | 15 (75.0%) | 2.04 (0.58–7.19) | 0.304 |
With carbapenems | 3 (5.3%) | 1 (5.0%) | 1.06 (0.10–10.77) | 1.000 |
With amikacin | 2 (3.6%) | 1 (5.0%) | 0.70 (0.06–8.21) | 1.000 |
With fluoroquinolones | 4 (7.0%) | 0 (0.0%) | 0.73 (0.63–0.84) | 0.568 |
Delayed tigecycline treatment | 19 (33.3%) | 2 (10.0%) | 4.50 (0.86–13.31) | 0.044 |